These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

369 related items for PubMed ID: 19141121

  • 1. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.
    Nyman H, Jerkeman M, Karjalainen-Lindsberg ML, Banham AH, Enblad G, Leppä S.
    Eur J Haematol; 2009 May; 82(5):364-72. PubMed ID: 19141121
    [Abstract] [Full Text] [Related]

  • 2. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study.
    Copie-Bergman C, Gaulard P, Leroy K, Briere J, Baia M, Jais JP, Salles GA, Berger F, Haioun C, Tilly H, Emile JF, Banham AH, Mounier N, Gisselbrecht C, Feugier P, Coiffier B, Molina TJ.
    J Clin Oncol; 2009 Nov 20; 27(33):5573-9. PubMed ID: 19786664
    [Abstract] [Full Text] [Related]

  • 3. Impact of germinal center and non-germinal center phenotypes on overall and failure-free survival after high-dose chemotherapy and auto-SCT in primary diffuse large B-cell lymphoma.
    Nyman H, Jantunen E, Juvonen E, Elonen E, Böhm J, Kosma VM, Enblad G, Karjalainen-Lindsberg ML, Leppä S.
    Bone Marrow Transplant; 2008 Jul 20; 42(2):93-8. PubMed ID: 18391989
    [Abstract] [Full Text] [Related]

  • 4. Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma.
    Sagaert X, de Paepe P, Libbrecht L, Vanhentenrijk V, Verhoef G, Thomas J, Wlodarska I, De Wolf-Peeters C.
    J Clin Oncol; 2006 Jun 01; 24(16):2490-7. PubMed ID: 16636337
    [Abstract] [Full Text] [Related]

  • 5. Absence of cyclin-D2 and Bcl-2 expression within the germinal centre type of diffuse large B-cell lymphoma identifies a very good prognostic subgroup of patients.
    Amen F, Horncastle D, Elderfield K, Banham AH, Bower M, Macdonald D, Kanfer E, Naresh KN.
    Histopathology; 2007 Jul 01; 51(1):70-9. PubMed ID: 17593082
    [Abstract] [Full Text] [Related]

  • 6. Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma.
    Banham AH, Connors JM, Brown PJ, Cordell JL, Ott G, Sreenivasan G, Farinha P, Horsman DE, Gascoyne RD.
    Clin Cancer Res; 2005 Feb 01; 11(3):1065-72. PubMed ID: 15709173
    [Abstract] [Full Text] [Related]

  • 7. Serum levels of inflammatory cytokines at diagnosis correlate to the bcl-6 and CD10 defined germinal centre (GC) phenotype and bcl-2 expression in patients with diffuse large B-cell lymphoma.
    Pedersen LM, Jürgensen GW, Johnsen HE.
    Br J Haematol; 2005 Mar 01; 128(6):813-9. PubMed ID: 15755285
    [Abstract] [Full Text] [Related]

  • 8. Prognostic significance of bcl-2, bax, and p53 expression in diffuse large B-cell lymphoma.
    Sohn SK, Jung JT, Kim DH, Kim JG, Kwak EK, Park Ti, Shin DG, Sohn KR, Lee KB.
    Am J Hematol; 2003 Jun 01; 73(2):101-7. PubMed ID: 12749011
    [Abstract] [Full Text] [Related]

  • 9. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
    Fu K, Weisenburger DD, Choi WW, Perry KD, Smith LM, Shi X, Hans CP, Greiner TC, Bierman PJ, Bociek RG, Armitage JO, Chan WC, Vose JM.
    J Clin Oncol; 2008 Oct 01; 26(28):4587-94. PubMed ID: 18662967
    [Abstract] [Full Text] [Related]

  • 10. FOXP1 protein overexpression is associated with inferior outcome in nodal diffuse large B-cell lymphomas with non-germinal centre phenotype, independent of gains and structural aberrations at 3p14.1.
    Hoeller S, Schneider A, Haralambieva E, Dirnhofer S, Tzankov A.
    Histopathology; 2010 Jul 01; 57(1):73-80. PubMed ID: 20579129
    [Abstract] [Full Text] [Related]

  • 11. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
    Thieblemont C, Briere J, Mounier N, Voelker HU, Cuccuini W, Hirchaud E, Rosenwald A, Jack A, Sundstrom C, Cogliatti S, Trougouboff P, Boudova L, Ysebaert L, Soulier J, Chevalier C, Bron D, Schmitz N, Gaulard P, Houlgatte R, Gisselbrecht C.
    J Clin Oncol; 2011 Nov 01; 29(31):4079-87. PubMed ID: 21947824
    [Abstract] [Full Text] [Related]

  • 12. The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome.
    Barrans SL, Evans PA, O'Connor SJ, Kendall SJ, Owen RG, Haynes AP, Morgan GJ, Jack AS.
    Clin Cancer Res; 2003 Jun 01; 9(6):2133-9. PubMed ID: 12796378
    [Abstract] [Full Text] [Related]

  • 13. Clinical impact of bulky mass in the patient with primary extranodal diffuse large B cell lymphoma treated with R-CHOP therapy.
    Song MK, Chung JS, Sung-Yong O, Lee GW, Kim SG, Seol YM, Shin HJ, Choi YJ, Cho GJ, Shin DH, Yun EY.
    Ann Hematol; 2010 Oct 01; 89(10):985-91. PubMed ID: 20428871
    [Abstract] [Full Text] [Related]

  • 14. Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study.
    Linderoth J, Jerkeman M, Cavallin-Ståhl E, Kvaløy S, Torlakovic E, Nordic Lymphoma Group Study.
    Clin Cancer Res; 2003 Feb 01; 9(2):722-8. PubMed ID: 12576441
    [Abstract] [Full Text] [Related]

  • 15. Prognostic impact of diffuse large B-cell lymphoma subgroups in patients undergoing autologous SCT.
    Hallack Neto AE, Dulley FL, Coelho Siqueira SA, Pracchia LF, Belesso M, Saboya R, Sturaro D, Amigo-Filho JU, Mendrone Junior A, Chamone DA, Pereira J.
    Bone Marrow Transplant; 2009 Feb 01; 43(4):323-5. PubMed ID: 18850022
    [Abstract] [Full Text] [Related]

  • 16. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab.
    Natkunam Y, Farinha P, Hsi ED, Hans CP, Tibshirani R, Sehn LH, Connors JM, Gratzinger D, Rosado M, Zhao S, Pohlman B, Wongchaowart N, Bast M, Avigdor A, Schiby G, Nagler A, Byrne GE, Levy R, Gascoyne RD, Lossos IS.
    J Clin Oncol; 2008 Jan 20; 26(3):447-54. PubMed ID: 18086797
    [Abstract] [Full Text] [Related]

  • 17. Expression and prognostic implications of cell cycle regulatory molecules, p16, p21, p27, p14 and p53 in germinal centre and non-germinal centre B-like diffuse large B-cell lymphomas.
    Paik JH, Jeon YK, Park SS, Kim YA, Kim JE, Huh J, Lee SS, Kim WH, Kim CW.
    Histopathology; 2005 Sep 20; 47(3):281-91. PubMed ID: 16115229
    [Abstract] [Full Text] [Related]

  • 18. The impact of P53 and P21(waf1) expression on the survival of patients with the germinal center phenotype of diffuse large B-cell lymphoma.
    Visco C, Canal F, Parolini C, Andreoli A, Ambrosetti A, Krampera M, Lestani M, Pizzolo G, Chilosi M.
    Haematologica; 2006 May 20; 91(5):687-90. PubMed ID: 16670073
    [Abstract] [Full Text] [Related]

  • 19. High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
    Hasselblom S, Hansson U, Olsson M, Torén L, Bergström A, Nilsson-Ehle H, Andersson PO.
    Br J Haematol; 2010 May 20; 149(4):560-8. PubMed ID: 20201946
    [Abstract] [Full Text] [Related]

  • 20. Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays.
    Zinzani PL, Dirnhofer S, Sabattini E, Alinari L, Piccaluga PP, Stefoni V, Tani M, Musuraca G, Marchi E, Falini B, Baccarani M, Pileri SA.
    Haematologica; 2005 Mar 20; 90(3):341-7. PubMed ID: 15749666
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.